Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: EXEL FATE KPTI ARGX IMTX MRNA AGEN ADAP AFMD IOVA

| Held by: IBB SBIO BBC MSSM GWX MEDX QQQS MEDI IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-3.63	Insider Own	11.08%	Shs Outstand	49.87M	Perf Week	-3.15%
Market Cap	276.61M	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-1.08%	Shs Float	44.40M	Perf Month	-15.81%
Enterprise Value	-365.24M	PEG	-	EPS next Q	-0.94	Inst Own	63.49%	Short Float	4.48%	Perf Quarter	-15.81%
Income	-250.99M	P/S	9.77	EPS this Y	-32.89%	Inst Trans	-6.88%	Short Ratio	6.36	Perf Half Y	-23.27%
Sales	28.31M	P/B	0.62	EPS next Y	2.13%	ROA	-28.51%	Short Interest	1.99M	Perf YTD	-21.75%
Book/sh	8.92	P/C	0.43	EPS next 5Y	-5.78%	ROE	-34.63%	52W High	13.11 -57.74%	Perf Year	-52.41%
Cash/sh	12.98	P/FCF	-	EPS past 3/5Y	-2.91% -0.87%	ROIC	-40.47%	52W Low	5.27 5.12%	Perf 3Y	-79.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	44.50% 20.56%	Gross Margin	76.01%	Volatility	5.98% 5.71%	Perf 5Y	-80.01%
Dividend TTM	-	EV/Sales	-12.90	EPS Y/Y TTM	-9.84%	Oper. Margin	-1169.04%	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.66	Sales Y/Y TTM	-23.43%	Profit Margin	-886.68%	RSI (14)	35.00	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	10.66	EPS Q/Q	-13.94%	SMA20	-12.80%	Beta	1.65	Target Price	20.73
Payout	-	Debt/Eq	0.01	Sales Q/Q	331.43%	SMA50	-17.59%	Rel Volume	0.82	Prev Close	5.63
Employees	305	LT Debt/Eq	0.00	Earnings	Oct 30 BMO	SMA200	-25.83%	Avg Volume	312.68K	Price	5.54
IPO	May 23, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.14% 46.50%	Trades		Volume	255,846	Change	-1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Hold	$19
Oct-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Nov-08-24	Initiated	Stephens	Equal-Weight	$25
Sep-06-24	Initiated	RBC Capital Mkts	Outperform	$35
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral	$33 → $28
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight	$30
Jul-06-22	Resumed	Canaccord Genuity	Buy	$60
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral	$62 → $33
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight	$100 → $80
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight	$60
Dec-17-21	Initiated	SVB Leerink	Outperform	$70
Dec-09-21	Initiated	Needham	Buy	$85
Sep-30-21	Initiated	B. Riley Securities	Buy	$56
Apr-20-21	Initiated	JMP Securities	Mkt Outperform	$53
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight	$30
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy	$25
Nov-14-19	Initiated	ROTH Capital	Buy	$17

Show Previous Ratings

Feb-03-26 07:00AM	Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline (Business Wire) -7.55%
Jan-12-26 07:00AM	Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 (Business Wire)
Dec-16-25 01:00AM	Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline (Business Wire)
Nov-12-25 04:05PM	Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-30-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results (Business Wire) +7.09%
04:05PM	Loading…
Sep-08-25 04:05PM	Bicycle Therapeutics Strengthens Board of Directors with New Appointments (Business Wire)
12:30AM	Analysts Positive on Bicycle Therapeutics (BCYC) After Q2 Results (Insider Monkey)
Aug-08-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 10:15AM	Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-02-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.83%
Jun-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-22-25 05:05PM	Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting (Business Wire)
May-15-25 03:00AM	Eckert & Ziegler SE (XTER:EUZ) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-05-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -18.32%
07:52AM	Is Bicycle Therapeutics plc (BCYC) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
02:01PM	Loading…
May-02-25 02:01PM	Bicycle Therapeutics price target lowered to $15 from $40 at Barclays (TipRanks)
May-01-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results (Business Wire) +6.07%
Apr-29-25 07:00AM	Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 (Business Wire)
Apr-22-25 03:47AM	Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted (Seeking Alpha) +16.24%
Apr-02-25 07:00AM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-01-25 07:00AM	Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -7.54%
Mar-27-25 07:00AM	Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments (Business Wire) +5.27%
Mar-05-25 07:00AM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-14-25 02:11PM	Bicycle Therapeutics (BCYC): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey)
Feb-05-25 07:00AM	Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.45%
Jan-13-25 07:00AM	Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones (Business Wire) +13.90%
Jan-09-25 07:00AM	Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:27PM	Loading…
Dec-20-24 03:27PM	First Solar, Frontier Communications, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-13-24 07:50AM	Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients (Benzinga) -31.33%
Dec-12-24 06:30PM	Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification (Business Wire)
Dec-10-24 07:00AM	Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts (Business Wire)
Dec-02-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-24 05:30PM	Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update (Business Wire)
Nov-13-24 10:39AM	Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 07:00AM	Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-01-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-31-24 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results (Business Wire)
Oct-23-24 07:00AM	Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals (Business Wire)
Oct-17-24 02:29PM	Bicycle Therapeutics (BCYC): High-Growth UK Stock with Innovative Peptide Technology (Insider Monkey)
Oct-16-24 07:00AM	Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress (Business Wire)
Oct-14-24 05:36AM	Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? (Zacks)
Oct-02-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-14-24 03:00AM	Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 (Business Wire)
Sep-06-24 01:37PM	Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone (Benzinga)
Sep-03-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-21-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-09-24 12:00PM	What Makes Bicycle Therapeutics (BCYC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? (Zacks)
Aug-06-24 01:53PM	BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +7.35%
07:05AM	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-22-24 07:00AM	Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024 (Business Wire) +6.94%
Jun-27-24 09:40AM	Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year? (Zacks)
Jun-11-24 09:40AM	Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
May-24-24 12:25PM	Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M (Zacks)
09:55AM	Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet (Zacks)
May-23-24 05:05PM	Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting (Business Wire) +9.62%
07:00AM	Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing (Business Wire)
May-21-24 09:40AM	Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year? (Zacks)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-06-24 12:00PM	Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade (Zacks) -5.21%
09:55AM	Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? (Zacks)
May-02-24 01:54PM	BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:44AM	Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress (GuruFocus.com)
07:00AM	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 10:05AM	Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting (Business Wire)
Apr-02-24 07:00AM	Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-05-24 04:35PM	Bicycle Therapeutics to Present at the AACR Annual Meeting 2024 (Business Wire)
Feb-28-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:05AM	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-07-24 07:00AM	Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-05-24 02:02AM	Bicycle Therapeutics PLC CEO Kevin Lee Sells 8,703 Shares (GuruFocus.com)
Dec-14-23 07:00AM	Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day (Business Wire) -8.93%
Nov-30-23 07:00AM	Bicycle Therapeutics to Host R&D Day on December 14 (Business Wire) +6.51%
Nov-02-23 08:46AM	Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day (GuruFocus.com)
07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day (Business Wire)
06:04AM	The Stage Is Set for a Rally: Canaccord Sees up to 290% Upside for These 3 Stocks (TipRanks)
Oct-30-23 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Oct-19-23 07:00AM	Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer (Business Wire)
04:00AM	Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director (GlobeNewswire)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks)
Sep-12-23 07:54AM	Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up (Zacks) -7.27%
06:36AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains? (Zacks)
Sep-11-23 02:19PM	Why Shares of Bicycle Therapeutics Were Rising on Monday (Motley Fool) +8.97%
07:00AM	Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer (Business Wire)
Sep-05-23 07:00AM	Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-03-23 06:59AM	Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-18-23 07:00AM	Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
06:45AM	Investors in Bicycle Therapeutics (NASDAQ:BCYC) have seen favorable returns of 39% over the past three years (Simply Wall St.)
Jul-14-23 06:47AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock? (Zacks)
Jul-13-23 06:40PM	Why Bicycle Therapeutics Stock Raced Ahead Today (Motley Fool) +19.32%
Jul-12-23 10:23PM	Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares (Business Wire) -6.70%
04:01PM	Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares (Business Wire)
Jun-23-23 07:30AM	Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer (Business Wire) -6.05%
Jun-13-23 07:00AM	Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit (Business Wire)

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 02 '26	Sale	6.80	1,317	8,956	67,380	Jan 06 08:00 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 05 '26	Sale	6.45	1,115	7,192	66,265	Jan 06 08:00 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jan 05 '26	Sale	6.46	3,266	21,098	161,966	Jan 06 08:00 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jan 02 '26	Sale	6.80	3,045	20,706	165,232	Jan 06 08:00 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jan 02 '26	Sale	6.80	2,827	19,224	100,275	Jan 06 08:00 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jan 05 '26	Sale	6.45	2,367	15,267	97,908	Jan 06 08:00 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jan 05 '26	Sale	6.46	3,416	22,067	136,717	Jan 06 08:00 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jan 02 '26	Sale	6.80	3,244	22,059	140,133	Jan 06 08:00 PM
Young Alethia	Chief Financial Officer	Jan 05 '26	Sale	6.49	4,334	28,123	87,081	Jan 06 08:00 PM
Young Alethia	Chief Financial Officer	Jan 02 '26	Sale	6.80	3,289	22,365	91,415	Jan 06 08:00 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jan 05 '26	Sale	6.46	10,989	70,989	618,996	Jan 06 08:00 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jan 02 '26	Sale	6.80	10,325	70,210	629,985	Jan 06 08:00 PM
Young Alethia	Officer	Jan 05 '26	Proposed Sale	6.53	123	803		Jan 05 04:29 PM
Milnes Alistair	Officer	Jan 02 '26	Proposed Sale	6.94	6,750	46,850		Jan 02 04:46 PM
Skynner Michael	Officer	Jan 02 '26	Proposed Sale	6.80	6,400	43,507		Jan 02 04:44 PM
Thompson Travis Alvin	Officer	Jan 02 '26	Proposed Sale	6.80	2,750	18,695		Jan 02 04:37 PM
Young Alethia	Officer	Jan 02 '26	Proposed Sale	6.80	7,500	50,985		Jan 02 04:36 PM
Hannay Michael Charles Ferguso	Officer	Jan 02 '26	Proposed Sale	6.80	5,250	35,690		Jan 02 04:35 PM
Lee Kevin	Officer	Jan 02 '26	Proposed Sale	6.80	21,500	146,157		Jan 02 04:31 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Oct 03 '25	Sale	8.41	3,231	27,173	475,310	Oct 06 04:45 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Oct 02 '25	Sale	8.40	2,263	19,009	478,541	Oct 06 04:45 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Oct 03 '25	Sale	8.41	978	8,225	118,277	Oct 06 04:45 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Oct 02 '25	Sale	8.40	824	6,922	119,255	Oct 06 04:45 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Oct 02 '25	Sale	8.40	1,147	9,635	94,355	Oct 06 04:45 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Oct 03 '25	Sale	8.41	978	8,225	93,377	Oct 06 04:45 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Oct 02 '25	Sale	8.40	473	3,973	53,352	Oct 06 04:45 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Oct 03 '25	Sale	8.41	250	2,102	53,102	Oct 06 04:45 PM
Young Alethia	Chief Financial Officer	Oct 02 '25	Sale	8.51	482	4,103	44,704	Oct 06 04:45 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Oct 02 '25	Sale	8.40	221	1,856	31,300	Oct 06 04:45 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Oct 03 '25	Sale	8.41	103	866	31,197	Oct 06 04:45 PM
Swanton Robert Charles	Director	Oct 02 '25	Sale	8.55	102	872	15,487	Oct 06 04:45 PM
Swanton Robert Charles	Director	Oct 02 '25	Proposed Sale	8.55	102	872		Oct 02 06:32 PM
Thompson Travis Alvin	Officer	Oct 02 '25	Proposed Sale	8.40	543	4,563		Oct 02 05:21 PM
Hannay Michael Charles Ferguso	Officer	Oct 02 '25	Proposed Sale	8.40	755	6,344		Oct 02 05:10 PM
Young Alethia	Officer	Oct 02 '25	Proposed Sale	7.09	486	3,447		Oct 02 04:47 PM
Lee Kevin	Officer	Oct 02 '25	Proposed Sale	8.40	5,958	50,061		Oct 02 04:41 PM
Milnes Alistair	Officer	Oct 02 '25	Proposed Sale	8.40	2,264	19,023		Oct 02 04:13 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jul 03 '25	Sale	7.44	3,193	23,756	480,804	Jul 07 05:20 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jul 02 '25	Sale	7.09	2,268	16,080	483,997	Jul 07 05:20 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jul 03 '25	Sale	7.44	966	7,187	120,079	Jul 07 05:20 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jul 02 '25	Sale	7.09	825	5,849	121,045	Jul 07 05:20 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jul 02 '25	Sale	7.09	1,149	8,146	96,468	Jul 07 05:20 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jul 03 '25	Sale	7.44	966	7,187	95,502	Jul 07 05:20 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jul 02 '25	Sale	7.09	474	3,361	54,073	Jul 07 05:20 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jul 03 '25	Sale	7.44	248	1,845	53,825	Jul 07 05:20 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jul 02 '25	Sale	7.09	206	1,461	31,621	Jul 07 05:20 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jul 03 '25	Sale	7.44	100	744	31,521	Jul 07 05:20 PM
Young Alethia	Chief Financial Officer	Jul 02 '25	Sale	7.09	204	1,446	45,186	Jul 07 05:20 PM
Young Alethia	Officer	Jul 02 '25	Proposed Sale	7.09	206	1,461		Jul 02 04:11 PM
Thompson Travis Alvin	Officer	Jul 02 '25	Proposed Sale	7.09	530	3,760		Jul 02 04:10 PM
Hannay Michael Charles Ferguso	Officer	Jul 02 '25	Proposed Sale	7.09	756	5,358		Jul 02 04:08 PM
Milnes Alistair	Officer	Jul 02 '25	Proposed Sale	7.09	2,266	16,066		Jul 02 04:07 PM
Skynner Michael	Officer	Jul 02 '25	Proposed Sale	7.09	1,942	13,769		Jul 02 04:06 PM
Lee Kevin	Officer	Jul 02 '25	Proposed Sale	7.09	5,963	42,287		Jul 02 04:04 PM
Young Alethia	Chief Financial Officer	Apr 02 '25	Sale	8.02	215	1,724	45,390	Apr 04 05:35 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Apr 03 '25	Sale	7.48	1,038	7,764	121,870	Apr 04 05:35 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Apr 02 '25	Sale	8.02	814	6,528	122,908	Apr 04 05:35 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Apr 03 '25	Sale	7.48	3,432	25,671	486,265	Apr 04 05:35 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Apr 02 '25	Sale	8.02	2,237	17,941	489,697	Apr 04 05:35 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Apr 02 '25	Sale	8.02	1,133	9,087	98,655	Apr 04 05:35 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Apr 03 '25	Sale	7.48	1,038	7,764	97,617	Apr 04 05:35 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Apr 02 '25	Sale	8.02	467	3,745	54,813	Apr 04 05:35 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Apr 03 '25	Sale	7.48	266	1,990	54,547	Apr 04 05:35 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Apr 02 '25	Sale	8.02	210	1,684	31,936	Apr 04 05:35 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Apr 03 '25	Sale	7.48	109	815	31,827	Apr 04 05:35 PM
Thompson Travis Alvin	Officer	Apr 02 '25	Proposed Sale	8.02	536	4,297		Apr 02 06:09 PM
Arroyo Santiago	Officer	Apr 02 '25	Proposed Sale	8.02	834	6,685		Apr 02 05:58 PM
Crockett Nigel	Officer	Apr 02 '25	Proposed Sale	8.02	1,757	14,084		Apr 02 05:52 PM
Skynner Michael	Officer	Apr 02 '25	Proposed Sale	8.02	1,931	15,479		Apr 02 05:47 PM
Hannay Michael Charles Ferguso	Officer	Apr 02 '25	Proposed Sale	8.02	749	6,004		Apr 02 05:33 PM
Lee Kevin	Officer	Apr 02 '25	Proposed Sale	8.02	5,932	47,550		Apr 02 05:25 PM
Young Alethia	Officer	Apr 02 '25	Proposed Sale	8.01	215	1,723		Apr 02 05:10 PM
Milnes Alistair	Officer	Apr 02 '25	Proposed Sale	8.02	2,250	18,036		Apr 02 05:05 PM

Open in Screener

PTCT

PTC Therapeutics Inc

Feb 11 • 04:00PM ET

70.92

-1.22 -1.69 %

Healthcare • Biotechnology • USA • NASD

PTCT PTC Therapeutics Inc daily Stock Chart

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: IJR VTI IWM VB XBI VBK VXF SPSM IJT IBB

Index	RUT	P/E	8.29	EPS (ttm)	8.56	Insider Own	4.10%	Shs Outstand	79.93M	Perf Week	-4.05%
Market Cap	5.69B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-14.25%	Shs Float	76.99M	Perf Month	-8.60%
Enterprise Value	4.42B	PEG	-	EPS next Q	0.10	Inst Own	105.80%	Short Float	13.09%	Perf Quarter	-2.15%
Income	751.72M	P/S	3.20	EPS this Y	303.69%	Inst Trans	14.99%	Short Ratio	6.35	Perf Half Y	56.66%
Sales	1.78B	P/B	-	EPS next Y	-111.11%	ROA	33.51%	Short Interest	10.08M	Perf YTD	-6.64%
Book/sh	-1.95	P/C	3.37	EPS next 5Y	-	ROE	-	52W High	87.50 -18.95%	Perf Year	45.82%
Cash/sh	21.02	P/FCF	8.07	EPS past 3/5Y	14.01% -2.04%	ROIC	-	52W Low	35.95 97.27%	Perf 3Y	55.87%
Dividend Est.	-	EV/EBITDA	4.62	Sales past 3/5Y	14.42% 21.32%	Gross Margin	95.78%	Volatility	3.89% 4.21%	Perf 5Y	12.08%
Dividend TTM	-	EV/Sales	2.48	EPS Y/Y TTM	261.84%	Oper. Margin	51.84%	ATR (14)	2.92	Perf 10Y	192.69%
Dividend Ex-Date	-	Quick Ratio	2.26	Sales Y/Y TTM	97.54%	Profit Margin	42.25%	RSI (14)	36.76	Recom	1.93
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	114.06%	SMA20	-4.97%	Beta	0.49	Target Price	88.50
Payout	-	Debt/Eq	-	Sales Q/Q	7.23%	SMA50	-6.55%	Rel Volume	0.54	Prev Close	72.14
Employees	939	LT Debt/Eq	-	Earnings	Feb 19 AMC	SMA200	16.16%	Avg Volume	1.59M	Price	70.92
IPO	Jun 20, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.65% 22.04%	Trades		Volume	864,700	Change	-1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$119
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$91
Oct-20-25	Initiated	Wells Fargo	Overweight	$73
Jun-17-25	Initiated	Truist	Buy	$80
May-09-25	Upgrade	BofA Securities	Neutral → Buy	$68
May-07-25	Upgrade	Citigroup	Sell → Neutral	$40
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28

Show Previous Ratings

Feb-05-26 08:00AM	PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 (PR Newswire)
Jan-27-26 08:21AM	Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-22-26 03:22AM	Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves (Insider Monkey)
Jan-12-26 08:30AM	PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference (PR Newswire)
04:30PM	Loading…
Jan-08-26 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-22-25 07:00AM	PTC Therapeutics Announces Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan (PR Newswire)
Dec-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.34%
Dec-18-25 08:00AM	PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.90%
09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 06:06PM	SanDisk stock surges after S&P 500 inclusion announcement (Investing.com)
06:01PM	Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Nov-20-25 08:00AM	PTC Therapeutics to Host R&D Day (PR Newswire)
Nov-05-25 12:02AM	PTC Therapeutics Inc (PTCT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.98%
06:00PM	Loading…
Nov-04-25 06:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates (Zacks)
04:21PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 07:24AM	What To Expect From PTC Therapeutics Inc (PTCT) Q3 2025 Earnings (GuruFocus.com)
Oct-31-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Oct-30-25 05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 12:24PM	Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 (Insider Monkey)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-21-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results (PR Newswire)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
Oct-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-11-25 11:15AM	PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU (Insider Monkey)
08:35AM	Loading…
Sep-05-25 08:35AM	Here's Why Shares in PTC Therapeutics Soared This Week (Motley Fool)
Sep-03-25 02:03PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily) +5.95%
Aug-29-25 04:52AM	PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich's Ataxia (Insider Monkey)
Aug-21-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
10:35AM	PTC Therapeutics CRL expected, focus moves to Sephience, says RBC Capital (TipRanks)
Aug-19-25 08:00AM	PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA (PR Newswire)
07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-07-25 06:00PM	PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -9.89%
05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
08:00AM	Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE (sepiapterin) (PR Newswire)
Jul-28-25 04:19PM	PTC Therapeutics Announces FDA Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire) +11.16%
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-21-25 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results (PR Newswire)
Jul-09-25 09:36AM	Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Jun-23-25 07:00AM	Sephience (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Jun-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-06-25 12:00PM	All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
May-10-25 10:35AM	PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 05:02AM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +12.63%
03:20AM	PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:19PM	PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
04:01PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
11:03AM	PTC Therapeutics price target lowered to $57 from $65 at RBC Capital (TipRanks)
May-05-25 04:54PM	Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? (Benzinga) -18.62%
09:29AM	Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result (GuruFocus.com)
08:22AM	PTC stock slides on new data for Huntingtons drug (BioPharma Dive)
07:00AM	PTC518 PIVOT-HD Study Achieves Primary Endpoint (PR Newswire)
May-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-25 09:00AM	PTC Therapeutics Receives Positive CHMP Opinion for Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Apr-24-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Apr-21-25 07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-17-25 10:01AM	PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.56%
Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '26	Sale	76.45	1,034	79,049	72,693	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 08 '26	Sale	76.50	4,602	352,057	82,887	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 09 '26	Sale	77.41	1,722	133,300	81,165	Jan 12 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 12 '26	Sale	78.70	1,024	80,589	80,141	Jan 12 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '26	Sale	76.45	2,514	192,195	394,453	Jan 12 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '26	Sale	76.45	866	66,206	92,428	Jan 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '26	Sale	76.56	4,033	308,760	113,626	Jan 12 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 09 '26	Sale	77.93	2,314	180,320	111,312	Jan 12 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '26	Sale	76.45	881	67,352	115,196	Jan 12 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '26	Sale	76.45	59	4,511	6,791	Jan 12 05:20 PM
Boulding Mark Elliott	Officer	Jan 09 '26	Proposed Sale	77.92	2,314	180,314		Jan 09 04:11 PM
Pauwels Eric	Officer	Jan 09 '26	Proposed Sale	77.89	2,746	213,889		Jan 09 04:09 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 06 '26	Sale	76.95	1,381	106,268	74,962	Jan 08 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '26	Sale	77.45	1,235	95,651	73,727	Jan 08 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jan 06 '26	Sale	76.95	2,139	164,596	90,310	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 06 '26	Sale	76.95	1,789	137,664	88,841	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 07 '26	Sale	77.48	1,352	104,753	87,489	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 06 '26	Sale	76.95	5,149	396,216	399,983	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '26	Sale	77.48	3,016	233,680	396,967	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	76.95	1,340	103,113	93,936	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '26	Sale	77.48	642	49,742	93,294	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Option Exercise	38.10	3,376	128,626	120,284	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Sale	77.44	4,879	377,825	117,659	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 06 '26	Sale	76.95	1,739	133,816	119,162	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	1,279	98,419	117,103	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	1,026	79,494	116,077	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	54	4,155	6,902	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	52	4,029	6,850	Jan 08 05:20 PM
Golden Lee Scott	Officer	Jan 08 '26	Proposed Sale	76.45	866	66,205		Jan 08 04:45 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.53	3,148	240,905		Jan 08 04:37 PM
Klein Matthew B.	Officer	Jan 08 '26	Proposed Sale	76.45	2,514	192,193		Jan 08 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '26	Proposed Sale	76.45	59	4,510		Jan 08 04:29 PM
Almstead Neil Gregory	Officer	Jan 08 '26	Proposed Sale	76.45	881	67,352		Jan 08 04:27 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.45	1,454	111,157		Jan 08 04:24 PM
Utter Christine Marie	Officer	Jan 08 '26	Proposed Sale	76.45	1,034	79,048		Jan 08 04:22 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.45	1,286	98,314		Jan 08 04:17 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.61	2,747	210,448		Jan 08 04:10 PM
Klein Matthew B.	Officer	Jan 07 '26	Proposed Sale	77.48	3,016	233,691		Jan 07 04:38 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.42	3,376	261,382		Jan 07 04:37 PM
Golden Lee Scott	Officer	Jan 07 '26	Proposed Sale	77.48	642	49,745		Jan 07 04:37 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.48	1,503	116,458		Jan 07 04:36 PM
Utter Christine Marie	Officer	Jan 07 '26	Proposed Sale	77.48	1,235	95,692		Jan 07 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '26	Proposed Sale	77.48	52	4,029		Jan 07 04:21 PM
Pauwels Eric	Officer	Jan 07 '26	Proposed Sale	77.48	1,352	104,758		Jan 07 04:17 PM
Almstead Neil Gregory	Officer	Jan 07 '26	Proposed Sale	77.48	1,026	79,498		Jan 07 04:14 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Option Exercise	39.42	2,266	89,326	123,167	Jan 06 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Sale	75.55	2,266	171,192	120,901	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Option Exercise	46.54	734	34,160	11,400	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Sale	76.00	734	55,784	10,666	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Option Exercise	30.86	12,000	370,320	30,500	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Sale	76.35	12,000	916,200	18,500	Jan 06 05:20 PM
Klein Matthew B.	Officer	Jan 06 '26	Proposed Sale	76.95	5,149	396,203		Jan 06 04:46 PM
Utter Christine Marie	Officer	Jan 06 '26	Proposed Sale	76.95	1,381	106,265		Jan 06 04:42 PM
Golden Lee Scott	Officer	Jan 06 '26	Proposed Sale	76.95	1,340	103,110		Jan 06 04:33 PM
Boulding Mark Elliott	Officer	Jan 06 '26	Proposed Sale	76.95	1,739	133,812		Jan 06 04:25 PM
Gravier Pierre	Officer	Jan 06 '26	Proposed Sale	76.95	2,139	164,591		Jan 06 04:25 PM
Almstead Zheng Yang	Member of immediate family of	Jan 06 '26	Proposed Sale	76.95	54	4,155		Jan 06 04:24 PM
Pauwels Eric	Officer	Jan 06 '26	Proposed Sale	76.95	1,789	137,659		Jan 06 04:16 PM
Almstead Neil Gregory	Officer	Jan 06 '26	Proposed Sale	76.95	1,279	98,416		Jan 06 04:15 PM
Boulding Mark Elliott	Officer	Jan 05 '26	Proposed Sale	76.00	2,266	172,216		Jan 05 02:00 PM
Reeve Emma	Director	Jan 05 '26	Proposed Sale	76.00	734	55,784		Jan 05 11:02 AM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 30 '25	Sale	76.64	8,089	619,941	341,875	Jan 02 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Proposed Sale	76.35	12,000	916,200		Jan 02 12:37 PM
Klein Matthew B.	Officer	Dec 30 '25	Proposed Sale	76.64	8,089	619,922		Dec 30 03:09 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Option Exercise	65.15	20,508	1,336,186	90,178	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Sale	77.26	20,508	1,584,350	70,373	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Option Exercise	62.06	40,290	2,500,282	105,734	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Option Exercise	62.69	3,202	200,732	73,204	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Sale	75.43	40,290	3,038,924	70,373	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Sale	75.06	3,202	240,351	70,373	Dec 19 05:20 PM
Pauwels Eric	Officer	Dec 19 '25	Proposed Sale	77.26	20,508	1,584,388		Dec 19 04:18 PM
SCHMERTZLER MICHAEL	Director	Dec 16 '25	Option Exercise	30.86	24,000	740,640	155,266	Dec 18 05:20 PM
Pauwels Eric	Officer	Dec 18 '25	Proposed Sale	75.06	3,202	240,354		Dec 18 04:30 PM
Pauwels Eric	Officer	Dec 17 '25	Proposed Sale	75.42	40,290	3,038,756		Dec 17 04:30 PM
Reeve Emma	Director	Dec 03 '25	Option Exercise	46.54	733	34,114	7,399	Dec 05 05:20 PM
Reeve Emma	Director	Dec 03 '25	Sale	78.62	733	57,628	6,666	Dec 05 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 02 '25	Sale	79.07	3,428	271,052	349,964	Dec 03 05:20 PM
Reeve Emma	Director	Dec 03 '25	Proposed Sale	78.62	733	57,628		Dec 03 10:40 AM
Klein Matthew B.	Officer	Dec 02 '25	Proposed Sale	79.07	3,428	271,063		Dec 02 03:11 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Option Exercise	30.75	71,928	2,211,679	148,249	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Sale	83.44	71,928	6,001,932	100,625	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Option Exercise	30.23	35,572	1,075,296	121,831	Nov 26 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Sale	80.18	35,572	2,852,031	100,625	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Option Exercise	15.00	14,199	213,017	25,351	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Option Exercise	14.73	11,801	173,883	23,551	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Sale	83.55	14,199	1,186,282	17,451	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Sale	80.14	11,801	945,736	17,451	Nov 26 05:20 PM
Reeve Emma	Director	Nov 21 '25	Option Exercise	51.16	10,000	511,600	16,666	Nov 25 05:20 PM
Reeve Emma	Director	Nov 21 '25	Sale	79.50	10,000	795,000	6,666	Nov 25 05:20 PM
Almstead Neil Gregory	Officer	Nov 25 '25	Proposed Sale	83.44	71,928	6,001,523		Nov 25 05:18 PM
Jacobson Allan Steven	Director	Nov 25 '25	Proposed Sale	83.45	14,199	1,184,975		Nov 25 04:23 PM
Almstead Neil Gregory	Officer	Nov 24 '25	Proposed Sale	80.18	35,572	2,852,154		Nov 24 04:34 PM
Jacobson Allan Steven	Director	Nov 24 '25	Proposed Sale	80.14	11,801	945,753		Nov 24 04:29 PM
Reeve Emma	Director	Nov 21 '25	Proposed Sale	79.50	10,000	795,000		Nov 21 04:38 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Option Exercise	25.69	2,812	72,240	106,713	Nov 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Sale	75.99	2,812	213,687	103,901	Nov 19 05:20 PM
Boulding Mark Elliott	Officer	Nov 17 '25	Proposed Sale	75.01	2,812	210,928		Nov 17 10:06 AM
Reeve Emma	Director	Nov 12 '25	Option Exercise	46.54	7,333	341,278	13,999	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Sale	74.50	7,333	546,308	6,666	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Proposed Sale	74.50	7,333	546,308		Nov 12 11:58 AM

BCYC

Bicycle Therapeutics Plc ADR

PTCT

PTC Therapeutics Inc

Upgrade your FINVIZ experience